Overlapping irritable bowel syndrome and inflammatory bowel disease: Less to this than meets the eye?

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 2, 2016, Pages 199-212

  Quigley, Eamonn M M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

fecal calprotectin; immune activation; inflammation; inflammatory bowel disease; irritable bowel syndrome; remission

Indexed keywords

CALGRANULIN;

BLOATING; CONSTIPATION; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; FECES ANALYSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE DISTENSION; INTESTINE ENDOSCOPY; INTESTINE FLORA; IRRITABLE COLON; LABORATORY TEST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REMISSION; REVIEW; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS;

EID: 84957888385     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15621230     Document Type: Review

References (139)

1. Agilli M., Aydin F., Gulcan K., Cayci T., (2015) Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders. Scand J Gastroenterol 50: 376-377.
2. Aguas M., Garrigues V., Bastida G., Nos P., Ortiz V., Fernandez A., et al. (2011) Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD). J Crohns Colitis 5: 227-233.
3. Akbar A., Yiangou Y., Facer P., Brydon W., Walters J., Anand P., et al. (2010) Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 59: 767-774.
4. Alibrahim B., Aljasser M., Salh B., (2015) Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review. Can J Gastroenterol Hepatol 29: 157-163.
5. Ananthakrishnan A., (2015) Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci 60: 290-298.
6. Arnott I., Kingstone K., Ghosh S., (2000) Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 35: 1163-1169.
7. Barbara G., Cremon C., Annese V., Basilisco G., Bazzoli F., Bellini M., et al. (2014a) Randomised controlled trial of mesalazine in IBS. Gut. DOI: 10.1136/gutjnl-2014-308188
8. Barbara G., Cremon C., Carini G., Bellacosa L., Zecchi L., De Giorgio R., et al. (2011) The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 17: 349-359.
9. Barbara G., Cremon C., Stanghellini V., (2014b) Inflammatory bowel disease and irritable bowel syndrome: similarities and differences. Curr Opin Gastroenterol 30: 352-358.
10. Barmeyer C., Schulzke J., Fromm M., (2015) Claudin-related intestinal diseases. Semin Cell Dev Biol 42: 30-38.
11. Barratt M., Leeds J., Robinson K., Lobo A., McAlindon M., Sanders D., (2011a) Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis. Dig Dis Sci 56: 3270-3275.
12. Barratt S., Leeds J., Robinson K., Shah P., Lobo A., McAlindon M., et al. (2011b) Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol 23: 159-165.
13. Bashashati M., Rezaei N., Andrews C., Chen C., Daryani N., Sharkey K., et al. (2012) Cytokines and irritable bowel syndrome: where do we stand? Cytokine 57: 201-209.
14. Bashashati M., Rezaei N., Shafieyoun A., McKernan D., Chang L., Öhman L., et al. (2014) Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 26: 1036-1048.
15. Bassotti G., Antonelli E., Villanacci V., Salemme M., Coppola M., Annese V., (2014) Gastrointestinal motility disorders in inflammatory bowel diseases. World J Gastroenterol 20: 37-44.
16. Beatty J., Bhargava A., Buret A., (2014) Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol 20: 3976-3985.
17. Bennet S., Öhman L., Simrén M., (2015) Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver 9: 318-331.
18. Bernstein C., (2015) Treatment of IBD: where we are and where we are going. Am J Gastroenterol 110: 114-126.
19. Berrill J., Green J., Hood K., Campbell A., (2013) Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 38: 44-51.
20. Berrill J., Sadlier M., Hood K., Green J., (2014) Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohns Colitis 8: 945-955.
21. Bharadwaj S., Barber M., Graff L., Shen B., (2015) Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle. Gastroenterol Rep 3: 185-193.
22. Biancone L., De Nigris F., Del Vecchio Blanco G., Monteleone I., Vavassori P., Geremia A., et al. (2002) Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther 16 (Suppl, 4): 29-33.
23. Björkesten C., Nieminen U., Turunen U., Arkkila P., Sipponen T., Färkkilä M., (2012) Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 47: 528-537.
24. Burgmann T., Clara I., Graff L., Walker J., Lix L., Rawsthorne P., et al. (2006) The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis-how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 4: 614-620.
25. Camilleri M., (2012) Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367: 1626-1635.
26. Camilleri M., (2015) Bile acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 9: 332-339.
27. Camilleri M., Katzka D., (2012) Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 302: 1075-1084.
28. Camilleri M., Lasch K., Zhou W., (2012a) Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 303: G775-G785.
29. Camilleri M., Madsen K., Spiller R., Greenwood-Van Meerveld B., Verne G., (2012b) Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 24: 503-512.
30. Canavan C., Card T., West J., (2014) The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: a cohort study. PLoS One 9: e106478.
31. Card T., Siffledeen J., Fleming K., (2014) Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J 2: 505-512.
32. Carroll I., Chang Y., Park J., Sartor R., Ringel Y., (2010) Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog 2: 19.
33. Carroll I., Ringel-Kulka T., Siddle J., Ringel Y., (2012) Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 24: 521-530.
34. Casén C., Vebø H., Sekelja M., Hegge F., Karlsson M., Ciemniejewska E., et al. (2015) Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther 42: 71-83.
35. Caviglia G., Pantaleoni S., Touscoz G., Adriani A., Rosso C., Smedile A., et al. (2014) Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol 49: 1419-1424.
36. Chang L., Adeyemo M., Karagiannides I., Videlock E., Bowe C., Shih W., et al. (2012) Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 107: 262-272.
37. Chassard C., Dapoigny M., Scott K., Crouzet L., Del'homme C., Marquet P., et al. (2012) Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 35: 828-838.
38. Cheung C., Wu J., (2014) Genetic polymorphism in pathogenesis of irritable bowel syndrome. World J Gastroenterol 20: 17693-17698.
39. Choung R., Locke G. 3rd, (2011) Epidemiology of IBS. Gastroenterol Clin North Am 40: 1-10.
40. Codling C., O'Mahony L., Shanahan F., Quigley E., Marchesi J., (2010) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55: 392-397.
41. Collins S., (2014) A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 11: 497-505.
42. Dalal S., Chang E., (2014) The microbial basis of inflammatory bowel diseases. J Clin Invest 124: 4190-4196.
43. D'Amato M., (2013) Genes and functional GI disorders: from casual to causal relationship. Neurogastroenterol Motil 25: 638-649.
44. Danese S., (2011) Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 300: 716-722.
45. David L., Surdea-Blaga T., Dumitrascu D., (2015) Semiquantitative fecal calprotectin test in postinfectious and non-postinfectious irritable bowel syndrome: cross-sectional study. Sao Paulo Med J 133: 343-349.
46. De Lange K., Barrett J., (2015) Understanding inflammatory bowel disease via immunogenetics. J Autoimmun 64: 91-100.
47. Del Valle-Pinero A., Martino A., Taylor T., Majors B., Patel N., Heitkemper M., et al. (2011) Pro-inflammatory chemokine C-C motif ligand 16 (CCL-16) dysregulation in irritable bowel syndrome (IBS): a pilot study. Neurogastroenterol Motil 23: 1092-1097.
48. De Palma G., Collins S., Bercik P., (2014) The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes 5: 419-429.
49. D'Haens G., Ferrante M., Vermeire S., Baert F., Noman M., Moortgat L., et al. (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18: 2218-2224.
50. Dhaliwal A., Zeino Z., Tomkins C., Cheung M., Nwokolo C., Smith S., et al. (2015) Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol 6: 14-19.
51. D'Inca R., Di Leo V., Corrao G., Martines D., D'Odorico A., Mestriner C., et al. (1999) Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 94: 2956-2960.
52. Dupont H., (2014) Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 39: 1033-1042.
53. Durbán A., Abellán J., Jiménez-Hernández N., Artacho A., Garrigues V., Ortiz V., et al. (2013) Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome. FEMS Microbiol Ecol 86: 581-589.
54. Fukuba N., Ishihara S., Tada Y., Oshima N., Moriyama I., Yuki T., et al. (2014) Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol 49: 674-680.
55. García Rodríguez L., Ruigómez A., Wallander M., Johansson S., Olbe L., (2000) Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol 35: 306-311.
56. Gearry R., Irving P., Barrett J., Nathan D., Shepherd S., Gibson P., (2009) Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 3: 8-14.
57. Ghoshal U., Shukla R., Ghoshal U., Gwee K., Ng S., Quigley E., (2012) The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012: 151085.
58. Gracie D., Ford A., (2014) Functional bowel symptoms in quiescent inflammatory bowel disease: more than just irritable bowel syndrome? Gastroenterology 147: 1176-1177.
59. Gracie D., Ford A., (2015) IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol 8: 101-109.
60. Grover M., Herfarth H., Drossman D., (2009) The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 7: 48-53.
61. Halpin S., Ford A., (2012) Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 107: 1474-1482.
62. Hod K., Ringel-Kulka T., Martin C., Maharshak N., Ringel Y., (2015) High-sensitive C-reactive protein as a marker for inflammation in irritable bowel syndrome. J Clin Gastroenterol. 23 2015. [Epub ahead of print]
63. Hutfless S., Abramson O., Heyman M., Bayless T., Li D., Winthrop K., et al. (2015) Infections requiring hospitalization as predictors of pediatric-onset Crohn's Disease and ulcerative colitis. Gastroenterol Res Pract 2015: article ID 690581.
64. Hyland N., Quigley E., Brint E., (2014) Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol 20: 8859-8866.
65. Isgar B., Harman M., Kaye M., Whorwell P., (1983) Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 24: 190-192.
66. Iskandar H., Cassell B., Kanuri N., Gyawali C., Gutierrez A., Dassopoulos T., (2014) Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 48: 423-429.
67. Jalanka-Tuovinen J., Salojärvi J., Salonen A., Immonen O., Garsed K., Kelly F., et al. (2014) Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63: 1737-1745.
68. Jelsnes-Jørgensen L., Bernklev T., Moum B., (2012) Fatigue and disease-related worries among inflammatory bowel disease patients in remission; is it a reflection of coexisting IBS-like symptoms? A short report. J Psychosom Res 73: 469-472.
69. Jelsness-Jørgensen L., Bernklev T., Moum B., (2013) Calprotectin is a useful tool in distinguishing coexisting irritable bowel-like symptoms from that of occult inflammation among inflammatory bowel disease patients in remission. Gastroenterol Res Pract 2013: 620707.
70. Jelsness-Jørgensen L., Bernklev T., Moum B., (2014) Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with impaired social functioning and increased bodily pain. Gastroenterol Nurs 37: 280-287.
71. Jeffery I., O'Toole P., Öhman L., Claesson M., Deane J., Quigley E., et al. (2012a) An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 61: 997-1006.
72. Jeffery I., Quigley E., Öhman L., Simrén M., O'Toole P., (2012b) The microbiota link to irritable bowel syndrome: an emerging story. Gut Microbes 3: 572-576.
73. Jonefjäll B., Simrén M., Öhman L., Lasson A., Svedlund J., Strid H., (2015) The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clinical remission. J Crohns Colitis 9: 776-783.
74. Jonefjäll B., Strid H., Öhman L., Svedlund J., Bergstedt A., Simrén M., (2013) Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. Neurogastroenterol Motil 25: 756-e578.
75. Kalantari H., Taheri A., Yaran M., (2015) Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome. Adv Biomed Res 4: 85.
76. Kassinen A., Krogius-Kurikka L., Mäkivuokko H., Rinttilä T., Paulin L., Corander J., et al. (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33.
77. Keohane J., O'Mahony C., O'Mahony L., O'Mahony S., Quigley E., Shanahan F., (2010) Irritable bowel syndrome type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 105: 1789-1794.
78. Keszthelyi D., Jonkers D., Hamer H., Masclee A., (2013) Letter: the role of sub-clinical inflammation and TRPV1 in the development of IBS-like symptoms in ulcerative colitis in remission. Aliment Pharmacol Ther 38: 560-561.
79. Kiank C., Tache Y., Larauche M., (2009) Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 24: 41-48.
80. Krogius-Kurikka L., Lyra A., Malinen E., Aarnikunnas J., Tuimala J., Paulin L., et al. (2009) Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 9: 95.
81. Kruis W., (2013) Commentary: symptoms of irritable bowel syndrome in patients with inflammatory bowel disease-organic disease or diseased organ? Aliment Pharmacol Ther 38: 440.
82. Kuo B., Bhasin M., Jacquart J., Scult M., Slipp L., Riklin E., et al. (2015) Genomic and clinical effects associated with a relaxation response mind-body intervention in patients with irritable bowel syndrome and inflammatory bowel disease. PLoS One 10: e0123861.
83. Levesque B., Sandborn W., Ruel J., Feagan B., Sands B., Colombel J., (2015) Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 148: 37-51.
84. Long M., Barnes E., Herfarth H., Drossman D., (2012) Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm Bowel Dis 18: 869-876.
85. Longstreth G., Thompson W., Chey W., Houghton L., Mearin F., Spiller R., (2006) Functional bowel disorders. Gastroenterology 130: 1480-1491.
86. Lopetuso L., Scaldaferri F., Bruno G., Petito V., Franceschi F., Gasbarrini A., (2015) The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci 19: 1068-1076.
87. Lopez-Siles M., Martinez-Medina M., Busquets D., Sabat-Mir M., Duncan S., Flint H., et al. (2014) Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish Irritable bowel syndrome and inflammatory bowel disease phenotypes. Int J Med Microbiol 304: 464-475.
88. MacDermott R., (2007) Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm Bowel Dis 13: 91-96.
89. Macsharry J., O'Mahony L., Fanning A., Bairead E., Sherlock G., Tiesman J., et al. (2008) Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 43: 1467-1476.
90. Major G., Spiller R., (2014) Irritable bowel syndrome, inflammatory bowel disease and the microbiome. Curr Opin Endocrinol Diabetes Obes 21: 15-21.
91. Matricon J., Meleine M., Gelot A., Piche T., Dapoigny M., Muller E., et al. (2012) Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 36: 1009-1031.
92. Mayer E., Savidge T., Shulman R., (2014) Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146: 1500-1512.
93. Mayer E., Tillisch K., Gupta A., (2015) Gut/brain axis and the microbiota. J Clin Invest 125: 926-938.
94. Menees S., Powell C., Kurlander J., Goel A., Chey W., (2015) A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 110: 444-454.
95. Minderhoud I., Oldenburg B., Wismeijer J., van Berge Henegouwen G., Smout A., (2004) IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci 49: 469-474.
96. Moayyedi P., (2014) ACP Journal Club. Review: Calprotectin testing differentiates inflammatory bowel disease from the irritable bowel syndrome. Ann Intern Med 160: JC13.
97. Naliboff B., Kim S., Bolus R., Bernstein C., Mayer E, Chang L., (2012) Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol 107: 451-459.
98. Neri M., (2013) Irritable bowel syndrome, inflammatory bowel disease and TRPV1: how to disentangle the bundle. Eur J Pain 17: 1263-1264.
99. Noor S., Ridgway K., Scovell L., Kemsley E., Lund E., Jamieson C., et al. (2010) Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol 10: 134.
100. Odenwald M., Turner J., (2013) Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol 11: 1075-1083.
101. Öhman L., Simrén M., (2010) Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 7: 163-173.
102. Öhman L., Törnblom H., Simrén M., (2015) Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 12: 36-49.
103. Oikonomou K., Kapsoritakis A., Theodoridou C., Karangelis D., Germenis A., Stefanidis I., et al. (2012) Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol 47: 519-530.
104. Olbe L., (2007) Concept of Crohn's disease being conditioned by four main components, and irritable bowel syndrome being an incomplete Crohn's disease. Scand J Gastroenterol 3: 1-8.
105. Overman E., Rivier J., Moeser A., (2012) CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha. PLoS One 7: e39935.
106. Parkes G., Rayment N., Hudspith B., Petrovska L., Lomer M., Brostoff J., et al. (2012) Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 24: 31-39.
107. Pastorelli L., De Salvo C., Mercado J., Vecchi M., Pizarro T., (2013) Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 4: 280.
108. Pellissier S., Dantzer C., Mondillon L., Trocme C., Gauchez A., Ducros V., et al. (2014) Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One 9: e105328.
109. Pike B., Paden K., Alcala A., Jaep K., Gormley R., Maue A., et al. (2015) Immunological biomarkers in postinfectious irritable bowel syndrome. J Travel Med 22: 242-250.
110. Pimentel M., Morales W., Rezaie A., Marsh E., Lembo A., Mirocha J., et al. (2015) Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One 10: e0126438.
111. Porter C., Cash B., Pimentel M., Akinseye A., Riddle M., (2012) Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. BMC Gastroenterol 12: 55.
112. Pozuelo M., Panda S., Santiago A., Mendez S., Accarino A., Santos J., et al. (2015) Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep 5: 12693.
113. Quigley E., (2013) Bugs on the brain; brain in the gut-seeking explanations for common gastrointestinal symptoms. Ir J Med Sci 182: 1-6.
114. Quigley E., Abdel-Hamid H., Barbara G., Bhatia S., Boeckxstaens G., De Giorgio R., et al. (2012) A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 46: 356-366.
115. Rajilić-Stojanović M., Biagi E., Heilig H., Kajander K., Kekkonen R., Tims S., et al. (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141: 1792-1801.
116. Rajilić-Stojanović M., Jonkers D., Salonen A., Hanevik K., Raes J., Jalanka J., et al. (2015) Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 110: 278-287.
117. Reinders C., Herulf M., Ljung T., Hollenberg J., Weitzberg E., Lundberg J., (2005) Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome. Clin Gastroenterol Hepatol 3: 777-783.
118. Ringel Y., Maharshak N., (2013) Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 305: G529-G541.
119. Rodríguez-Fandiño O., Hernández-Ruiz J., Schmulson M., (2010) From cytokines to toll-like receptors and beyond-current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil 16: 363-373.
120. Sands B., (2015) Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 149: 1275-1285.
121. Saulnier D., Riehle K., Mistretta T., Diaz M., Mandal D., Raza S., et al. (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141: 1782-1791.
122. Schoepfer A., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F., (2008) Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 14: 32-39.
123. Schwender B., Floch M., (2012) Should FODMAP withdrawal be tried in inflammatory bowel disease patients with irritable bowel syndrome? J Clin Gastroenterol 48: 393-394.
124. Shanahan F., Bernstein C., (2009) The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol 25: 301-305.
125. Simrén M., Axelsson J., Gillberg R., Abrahamsson H., Svedlund J., Bjornsson E., (2002) Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 97: 389-396.
126. Simrén M., Barbara G., Flint H., Spiegel B., Spiller R., Vanner S., et al. (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62: 159-176.
127. Stanisic V., Quigley E., (2014) The overlap between IBS and IBD: what is it and what does it mean? Expert Rev Gastroenterol Hepatol 8: 139-145.
128. Sundin J., Rangel I., Fuentes S., Heikamp-de Jong I., Hultgren-Hörnquist E., de Vos W., et al. (2015) Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 41: 342-351.
129. Tang L., Nabalamba A., Graff L., Bernstein C., (2008) A comparison of self-perceived health status in inflammatory bowel disease and irritable bowel syndrome patients from a Canadian national population survey. Can J Gastroenterol 22: 475-483.
130. Theoharides T., (2014) Mast cells in irritable bowel syndrome and ulcerative colitis: function not numbers is what makes all the difference. Dig Dis Sci 59: 897-898.
131. Van Limbergen J., Russell R., Nimmo E., Ho G., Arnott I., Wilson D., et al. (2007) Genetics of the innate immune response in inflammatory bowel disease. Inflamm Bowel Dis 13: 338-355.
132. Vermeire S., Van Assche G., Rutgeerts P., (2011) Inflammatory bowel disease and colitis: new concepts from the bench and the clinic. Curr Opin Gastroenterol 27: 32-37.
133. Vilela E., Torres H., Martins F., Ferrari Mde L., Andrade M., Cunha A., (2012) Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol 18: 872-881.
134. Villani A., Lemire M., Thabane M., Belisle A., Geneau G., Garg A., et al. (2010) Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 138: 1502-1513.
135. Vivinus-Nébot M., Dainese R., Anty R., Saint-Paul M., Nano J., Gonthier N., et al. (2012) Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 107: 75-81.
136. Vivinus-Nébot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., et al. (2014) Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63: 744-752.
137. Von Stein P., Lofberg R., Kuznetsov N., Gielen A., Persson J., Sundberg R., et al. (2008) Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome. Gastroenterology 134: 1869-1881.
138. Waugh N., Cummins E., Royle P., Kandala N., Shyangdan D., Arasaradnam R., et al. (2013) Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 17: 1-211.
139. Zhou X., Xu W., Tang X., Luo L., Tu J., Zhang C., et al. (2014) Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol 14: 121.